Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Volume Zscore is a recent 2 week high. A recent surge of ZScore means trading activities is accelerating at a record speed.
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
- MACD is crossing MACD signal line at 1.0. MACD crossing signal line is bullish signal.
| MarketCap | 1.2B |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| P/B | 16.8 |
| P/S (ttm) | 5.7 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 5% |
| Held by Institutions % | 25% |
| 1 Day Vol Adjusted Return | -1.2 |
| 1 Month Vol Adjusted Return | 8.8 |
| 3 Month Vol Adjusted Return | 14.3 |
| 6 Month Vol Adjusted Return | 13.0 |
| 20 Days SMA Price ZScore | 1.9 |
| 50 Days SMA Price ZScore | 3.2 |
| 12 -26 Days PPO | 27.0 |
| 1 Month Average Short Volume Ratio | 44.3 |
| 1 Day Volume Change ZScore | 0.8 |
| 1 Month Daily Vol | 21.7 |
Stock news
ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study "Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19" were published Feb. 20 on medRxiv, a preprint publication website. The Phase 3 study demonstrated that patients with mild-to-moderate COVID-19 receiving standard of care experienced a 3.5 day reduction in recovery time when receiving an added nutritional protocol. Aimed at improving mitochondrial function, the protocol included nicotinamide ribos...
ChromaDex Corp. (NASDAQ: CDXC) announced today that it has entered into a securities purchase agreement for the sale of $25.0 million of its common stock in a private placement. The private placement was led by a new international investor and is expected to close on or about February 23, 2021, subject to the satisfaction of customary closing conditions. In connection with the investment, the Company agreed to sell 3,846,153 shares of its common stock at a per share price of $6.50, for gross pro...
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if...
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., March 10, 2021 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended December 31, 2020. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
ChromaDex was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Founded in 1999, ChromaDex Corp (NASDAQ: CDXC) is a bioscience company that is focused on healthy aging. The company is pioneering research and discoveries centered around nicotinamide adenine dinucleot...
ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study "Combined Metabolic Cofactor Supplementation Reduces Liver Fat in Nonalcoholic Fatty Liver Disease" were published on Cell Press Sneak Peek, a preprint publication website for papers under review by Cell Press Journals. The Phase 2 study reported a reduction in liver fat and inflammatory markers in patients with non-alcoholic fatty liver disease (NAFLD) when receiving a nutritional protocol including nicotinamide riboside (NR)...
Every investor in ChromaDex Corporation ( NASDAQ:CDXC ) should be aware of the most powerful shareholder groups...
ChromaDex (CDXC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.